Dr. Rachael Turner received her medical degree and her PhD from the University at Buffalo School of Medicine and Biomedical Sciences in 2013. Dr. Turner then completed her Internal Medicine Residency and Medical Oncology Fellowship at the University of Rochester Medical Center in 2015 and 2018, respectively. She is currently pursuing a Research Fellowship at the University of Rochester Medical Center. Dr. Turner is certified by the American Board of Internal Medicine.

Dr. Turner's special interests are women's cancers, including fallopian, ovarian, uterine and cervical. She is also interested in immune therapies for cancer. Dr. Turner is committed to providing personalized cancer care with compassion and dedication.

During her free time, Dr. Turner enjoys spending time with her husband and sons, running and hiking.

Faculty Appointments

Assistant Professor - Department of Medicine, Hematology/Oncology (SMD)

Assistant Professor - Department of Obstetrics and Gynecology (SMD) - Joint

Credentials

Residency & Fellowship

Fellowship, Hematology & Oncology, University of Rochester Medical Center. 2015 - 2018

Residency, Internal Medicine, University of Rochester Medical Center. 2014 - 2015

Internship, Internal Medicine, University of Rochester Medical Center. 2013 - 2014

Education

MD | SUNY at Buffalo-School of Medicine & Biomedical Sciences (USA). 2013

Awards

Internal Medicine Department Faculty Pilot Award. 2020 - 2021

Technology Development Fund Grant. 2019 - 2020

W.G Stuber Research Award. 2019 - 2020

Wilmot Fellowship Award. 2018

Conquer Cancer Foundation/Women who Conquer Cancer- Young Investigator Award. 2018

Best Overall Poster Presentation for HE4 in Ovarian Cancer Immune Suppression Poster Presentation. 2017

Harold Brody Award for Translational Research. 2011

Honorable Mention for poster presentation on Chronic Chemoimmunotherapy etc... 2010

Breast Cancer Pre-doctoral Traineeship Award. 2009 - 2011

Guy A. Bailey Outstanding Senior Award. 2005

Phi Beta Kappa National Honor Society. 2005

Tri-Beta Honor Society. 2004

Publications

Journal Articles

HE4 Overexpression by ovarian cancer promotes a suppressive tumor immune microenvironment and enhanced tumor and macrophage PD-L1 expression. Published online April 26,2021:

Rowswell-Turner R; Singh R; Urh A; Yano N; Kim K; Khazan K; Pandita, R; Sivagnanalingam U; Hovanesian V; James N; Ribeiro J; Kadambi S; Linehan D; Moore R.

J Immunol. 2021; .

Development of Potent Forchlorfenurone Analogs and Their Cytotoxic Effect in Cancer Cell Lines.

Kim KK; Singh RK; Khazan N; Kodza A; Singh NA; Jones A; Sivagnanalingam U; Towner M; Itamochi H; Turner, R; Moore RG.

Sci Rep. 2020; 10(1): 3241.

Role of trypsin and protease-active receptor-2 in ovarian cancer.

Kim KK; Turner R; Khazan N; Kodza A; Jones A; Singh RK; Moore RG.

PLOS One. 2020; 15(5): e0232253.

The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes.

James NE; Emerson JB; Borstadt; Beffa L; Liver MT; Hovanesian V; Urh A; Singh RK; Rowswell-Turner R; DiSilvestro PA; Ou J; Moore RG; Ribeiro JR.

Sci Rep. 2020; 10(1): 8558.

Novel small molecule MEK inhibitor URML-3881 enhances cisplatin sensitivity in clear cell ovarian cancer.

Rowswell-Turner R; Rutishauser J; Kim KK.

Translat Oncol. 2019; 12(7): 914-924.

Human Epididymis Secretory Protein 4 (HE4) Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6.

James NE, Oliver MT, Ribeiro JR, Cantillo E, Rowswell-Turner RB, Kim KK, Chichester CO, DiSilvestro PA, Moore RG, Singh RK, Yano N, Zhao TC

Frontiers in pharmacology.. 2019 10 :216. Epub 03/19/2019.

HE4 suppresses the expression of osteopontin in mononuclear cells and compromises their cytotoxicity against ovarian cancer cells. Clin Exp Immunol. Epub ahead of print.

James, N.E.; Cantillo, E. ;Oliver, M.T.; Rowswell-Turner, R.B.

2018; .

Novel small molecule MEK inhibitor URML-3881 enhances cisplatin sensitivity in clear cell ovarian cancer. Manuscript submitted for publication.

Rowswell-Turner R, Rutishauser J, Kim KK et al.

2018; .

Treatment of chronic lymphocytic leukemia in older adults.

Rowswell-Turner, R.B; and Barr, P.

J Geriatric Oncology. 2017; 8(5): 315-319.

Chemoimmunotherapy as long-term maintenance therapy for cancer.

Egilmez, N.K.; Harden, J.L.; Rowswell-Turner, R.B.

Onco Immunology. 2012; 1(4): 1-3.

2012. Magnetic resonance spectroscopy of adult thalamic glioblastoma multiforme. N Am J Med Sci. 5(1):51-54.

Li, P.; Liu, Y.; Rowswell-Turner,R. B.; Esfahani, F.

2012; .

Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulation.

Rowswell-Turner, R.B.; Harden, J.L.; Nair,R.E;, Gu,T.; Kilinc,M.O.; Egilmez, N.K.

J Immunology. 2011; 187(8): 4109-18.

Dichotomous effects of IFN-y on dendritic cell function determine the extent of IL-12-driven antitumor T-cell immunity.

Harden, J.L.; Gu, T.; Kilinc, M.O.; Roswell-Turner, R.B.; Virtuoso, L.P.; Egilmez, N.K.

J Immunology. 2011; 187(1): 126-32.

Central Role of IFNgamma-indoleamine 2,3- dioxygenase axis in regulation of interleukin- 12- mediated antitumor immunity.

Gu, T.; Roswell-Turner, R.B.; Kilinc, M.O.; Egilmez, N.K.

Cancer Res. 2010; 70(1): 129-38.

Activated CD8+ T-effector/memory cells eliminated CD4+CD25+Foxp3+ T- suppressor cells from tumors via FasL mediated apoptosis

Kilinc, M.O.; Roswell-Turner, R.B.; Gu, T.; Virtuoso, L.P.; Egilmez, N.K.

J Immunology. 2009; 183(12): 7656-60.